Medicare GLP-1 coverage changed fundamentally on July 1, 2026. For the first time, Medicare beneficiaries can access brand-name semaglutide and tirzepatide for weight loss at a flat $50 per month. No step therapy, no prior authorization, no "cardiovascular indication only" requirement. The Medicare Annual Enrollment Period (AEP) begins October 15 and runs through December 7. If you're on Medicare and considering GLP-1 therapy, the next three weeks are when your coverage decisions happen.
By Alexandru Vieru | Independently researched | Updated September 2026. Information reflects CMS guidance and FDA public records through September 2026.
Bottom line: The Medicare GLP-1 Bridge Program offers $50/month brand-name access for eligible Part D enrollees through December 31, 2027. If you're already on Medicare with Part D coverage, you may not need to change your plan to access it. But the AEP is still your best window to check if your current plan will cover GLP-1 medications in 2027, when the Bridge Program expires. If you're not on Medicare, this article also covers how compounded semaglutide from licensed 503A clinics compares against the new brand-name pricing.
What the Medicare GLP-1 Bridge Program Covers in 2026
The Centers for Medicare & Medicaid Services (CMS) launched the GLP-1 Bridge Program on July 1, 2026. The full announcement is on the CMS newsroom.
What the program provides:
- $50 per month flat copay for covered GLP-1 weight-loss medications
- No step therapy. You do not have to fail a prior therapy first
- Runs through December 31, 2027. Giving patients 18 months of access while Congress and CMS work on longer-term coverage structures
Medications covered under the Bridge Program:
| Medication | Type | Weight-loss indication |
|---|---|---|
| Wegovy (semaglutide injection) | Weekly injection | ✅ Yes. Weight management |
| Semaglutide oral tablets | Daily pill | ✅ Yes. Weight management |
| Zepbound (tirzepatide KwikPen) | Weekly injection | ✅ Yes. Weight management |
| Foundayo (orforglipron) | Daily oral tablet | ✅ Yes. Newest FDA-approved |
Who is eligible:
You must be enrolled in a Medicare Part D prescription drug plan. The Bridge Program operates outside standard Part D benefit payment flow, meaning your plan's formulary does not determine whether you access these medications at $50/month. If you have Part D, you can access the Bridge Program.
What it does not cover:
- Medicare Advantage plans without prescription drug benefits (Part C without Part D)
- Compounded semaglutide from 503A pharmacies. Those remain separate cash-pay products
- Ozempic, Mounjaro, or Rybelsus when prescribed only for diabetes management (different indication, different coverage rules)
For the complete mechanics of how the Bridge Program works (including the formulary interaction, pharmacy process, and income-related adjustments) see our Medicare GLP-1 Bridge Program 2026 guide.
Medicare Annual Enrollment Period 2026: What Happens October 15. December 7
The Medicare AEP is your annual window to review and change your Medicare coverage. Decisions made during AEP take effect January 1, 2027.
Key AEP facts for GLP-1 users:
- October 15. December 7, 2026: AEP open window
- January 1, 2027: Changes take effect
- December 31, 2027: Medicare GLP-1 Bridge Program expires
The Bridge Program gives you brand-name GLP-1 access through December 2027 under your current Part D plan. But in 2028, coverage reverts to standard Part D rules. Which means your plan's formulary and prior authorization requirements will determine your access and out-of-pocket cost.
The AEP action to take now: Use the AEP to compare whether your Part D plan will cover GLP-1 medications in 2027–2028 at a cost that works for you. Some Part D plans are adding GLP-1 medications to their formulary for 2027 at copays well below retail. Others are not. The Medicare Plan Finder at medicare.gov lets you compare based on your specific medications.
If you're switching to Medicare Advantage in 2026: Some Medicare Advantage plans are adding GLP-1 weight-loss benefits in their 2027 bids. Compare these carefully: a plan that covers GLP-1 at $50/month copay in 2027 may be worth higher premiums if you expect to stay on therapy long-term.
Should You Switch Medicare Plans to Get Better Medicare GLP-1 Coverage?
For most current Medicare beneficiaries, the answer is: probably not in 2026, because the Bridge Program already gives you $50/month access. Switching plans to get a benefit you already have through the Bridge Program is unnecessary disruption.
When switching might make sense:
- Your current Part D plan's formulary will NOT cover GLP-1 in 2027. Once the Bridge Program expires (December 31, 2027), you will revert to your plan's standard rules. If your plan doesn't cover Wegovy or Zepbound, your cost could jump from the $50/month Bridge copay to the self-pay price: at today's prices, $349/month for the Wegovy pen through NovoCare or $299 to $449/month for Zepbound through LillyDirect (checked 12 October 2026). Switching to a plan with formulary coverage during AEP 2026 protects your 2028 access.
- Your current plan requires step therapy for 2027 coverage. Some Part D plans covering GLP-1 still require prior authorization or step therapy in their standard benefit. If you're planning to be on GLP-1 long-term, a plan with fewer barriers matters.
- You're currently not on Medicare and turning 65 in 2027. Your Initial Enrollment Period (IEP), not AEP, is your first window. Choosing a Part D plan with GLP-1 coverage from the start avoids a coverage gap.
What to check before switching:
- Does the plan's 2027 formulary include Wegovy or Zepbound (not just Ozempic/Mounjaro for diabetes)?
- What is the 2027 copay tier and prior authorization requirement for weight-loss GLP-1?
- Does the plan premium increase offset the formulary savings?
Compounded vs Brand-Name Medicare GLP-1: The Updated Math
For patients not on Medicare, the traditional calculus was straightforward: brand-name GLP-1 medications cost far more than compounded. Today the manufacturers' self-pay prices are $349 a month for the Wegovy pen through NovoCare and $299 to $449 for Zepbound through LillyDirect (checked 12 October 2026), while compounded semaglutide runs $49–$199 per month from licensed telehealth clinics, and the math clearly favored compounded for the large majority of cash-paying patients.
The Medicare GLP-1 Bridge Program changes this math significantly for Medicare beneficiaries:
| Coverage path | Monthly cost | Medications available | Requires insurance |
|---|---|---|---|
| Medicare Bridge Program (brand-name) | $50/month | Wegovy, Zepbound, Foundayo | Yes. Part D required |
| Compounded 503A telehealth | $49–$199/month | Compounded sema, compounded tirz | No. Cash pay |
| Commercial Part D (no Bridge) | $150–$400/month | Formulary-dependent | Yes |
| Brand-name self-pay (no insurance) | Wegovy pen $349/month via NovoCare; Zepbound $299 to $449/month via LillyDirect | All FDA-approved | No |
If you're on Medicare with Part D: The Bridge Program at $50/month is almost certainly a better deal than compounded semaglutide from a cash-pay telehealth clinic. Brand-name Wegovy or Zepbound at $50/month through Medicare is the superior value. Better medication certainty, FDA-approved labeling, and manufacturer pharmacovigilance.
If you're NOT on Medicare: Compounded semaglutide from a licensed 503A telehealth clinic remains the most cost-effective access route. The $50/month Medicare price is not available to the general public. It's exclusive to Medicare Part D enrollees through the Bridge Program.
For the full cost-versus-access breakdown, see our GLP-1 insurance coverage guide and the brand vs. compounded semaglutide cost analysis.
If You're Not on Medicare: Your GLP-1 Access Options for Q4 2026
For non-Medicare patients (those on employer plans, ACA marketplace plans, or paying cash) the Medicare Bridge Program does not apply. Your options in Q4 2026:
Option 1: Employer plan open enrollment (October–November)
Most employer plans hold open enrollment in October or November, with January 1 effective dates. This is your window to check whether your 2027 plan formulary covers Zepbound or Wegovy and at what copay tier. For a full decision framework on using employer open enrollment to access GLP-1, see our GLP-1 & Open Enrollment 2026 guide.
Option 2: ACA marketplace open enrollment (November 1. January 15)
ACA marketplace plans have been adding GLP-1 coverage for weight loss following the Medicare expansion. Open enrollment runs November 1, 2026, through January 15, 2027. Check HealthCare.gov for plan-by-plan formulary details.
Option 3: Licensed 503A telehealth clinics (cash pay, no insurance required)
Compounded semaglutide and tirzepatide from licensed telehealth clinics remain legal and available as of September 2026. The regulatory situation is unchanged: 503A compounding, where a licensed clinician writes a prescription for you specifically, operates under a different legal framework than the 503B outsourcing facilities targeted by the April 2026 proposed rule.
Current prices from licensed clinics in our ranking (verified June–August 2026):
| Clinic | Compounded sema | Compounded tirzepatide | Lock-in |
|---|---|---|---|
| Welludr (formerly Wellmedr) | $49/month | $89/month | Month-to-month |
| Wellorithm | $247/month ($147 first month) | $249/month | Month-to-month |
| Gala Health | $129/month on a $1,677 prepaid year | Available | Cancel anytime |
For the full ranking and cheapest compounded semaglutide options, including clinics with multi-month commitment tiers, see our ranked comparison.
Medicare GLP-1 Coverage and Brand-Name Clinic Access in 2026
One advantage of brand-name GLP-1 access under Medicare, or under commercial insurance, is the ability to use clinics that specialize in brand-name therapy. Not every telehealth GLP-1 program offers brand-name Wegovy and Zepbound, but some specifically support patients transitioning from compounded to brand-name.
For Medicare beneficiaries accessing brand-name GLP-1 through the Bridge Program:
Any in-network pharmacy can fill a Wegovy or Zepbound prescription at the $50 Bridge Program rate. You do not need a GLP-1 telehealth clinic. Your primary care physician or any licensed prescriber can write the prescription.
However, if you want ongoing clinical monitoring, titration support, and care navigation alongside your Medicare GLP-1 coverage, telehealth programs that handle brand-name prescriptions are an option:
Wellorithm explicitly supports brand-name Wegovy, Ozempic, Mounjaro, and Zepbound alongside compounded options on a single platform. If your Medicare coverage covers brand-name GLP-1 and you want a telehealth program for clinical oversight and titration management, this is worth considering. Starting at $247/month ($147 first month) for compounded; brand-name pathway available.
Gala Health is our Best Overall pick for its breadth of medication options and clinical oversight quality. Accepts patients seeking both compounded and brand-name options; pricing via intake.
Welludr offers the lowest-cost cash-pay entry point ($49/month for compounded semaglutide, $89/month for tirzepatide) for patients not yet on Medicare or whose Medicare coverage hasn't taken effect yet.
Frequently Asked Questions: Medicare GLP-1 Coverage 2026
Does Medicare GLP-1 coverage require prior authorization?
Under the Bridge Program specifically, no. The $50/month Bridge access is designed to bypass standard prior authorization requirements. Standard Part D coverage for 2027 and beyond will vary by plan. Check your specific plan's 2027 formulary.
Does Medicare cover compounded semaglutide?
No. Medicare Part D covers FDA-approved, brand-name medications. Compounded semaglutide prepared by a 503A pharmacy is not an FDA-approved product and is not covered by Medicare. If you're on Medicare, brand-name GLP-1 through the Bridge Program at $50/month is a better option than paying cash for compounded.
Is the Medicare GLP-1 Bridge Program available to Medicare Advantage members?
Yes, if your Medicare Advantage plan includes Part D prescription drug coverage. Most Medicare Advantage plans include Part D (these are called MA-PD plans). Check your plan's Summary of Benefits to confirm Part D is included.
What happens when the Bridge Program ends December 31, 2027?
You revert to your Part D plan's standard formulary rules. This is why the AEP this October matters: your 2027 plan selection determines your 2028 access and cost when the Bridge Program expires.
Will the FDA 503B rule affect my Medicare GLP-1 coverage?
No. The FDA 503B rulemaking targets large-scale compounding operations, not Medicare coverage of brand-name GLP-1 medications. Your Bridge Program access to Wegovy and Zepbound is governed by CMS rules, not the FDA compounding framework. For background on the 503B situation, see our Compounded Semaglutide FDA Update: Q3 2026.
I'm not on Medicare. Should I get on it for GLP-1 coverage?
Medicare has age and disability eligibility requirements. You cannot enroll solely to access the Bridge Program. If you are eligible for Medicare (typically 65+, or with qualifying disability), and you're currently paying cash for compounded GLP-1, enrolling may reduce your cost from $99–$199/month to $50/month for brand-name products.
Disclaimer and Disclosure
Compounded semaglutide and tirzepatide are not FDA-approved medications. They are prepared by licensed pharmacies under 503A regulations based on individual prescriptions from licensed clinicians. The FDA has issued guidance on compounded GLP-1 medications; consult a licensed healthcare provider before starting any GLP-1 therapy.
This site uses affiliate links. If you visit a clinic through our links and make a purchase, we may earn a commission at no extra cost to you. Our editorial rankings and scores are independent of affiliate arrangements. See our editorial policy and affiliate disclosure.
Last updated: September 2026.
Top Picks for GLP-1 Access in Q4 2026
Visit Wellorithm →. 7.9/10 · From $247/month ($147 first month) · Brand-name AND compounded options on one platform. Best choice if your coverage situation changes.
Visit Gala Health →. Best Overall · From $129/month on a $1,677 prepaid year · Broadest medication options, strong clinical oversight.
Visit Welludr →. From $49/month · Lowest cash-pay entry point. No lock-in.
Compare all ranked GLP-1 clinics →
